135 related articles for article (PubMed ID: 38000456)
1. Targeting PKM2 improves the gemcitabine sensitivity of intrahepatic cholangiocarcinoma cells via inhibiting β-catenin signaling pathway.
Yu W; Zeng F; Xiao Y; Chen L; Qu H; Hong J; Qu C; Cheng G
Chem Biol Interact; 2024 Jan; 387():110816. PubMed ID: 38000456
[TBL] [Abstract][Full Text] [Related]
2. Alpha5 nicotine acetylcholine receptor subunit promotes intrahepatic cholangiocarcinoma metastasis.
Fu Y; Shen K; Wang H; Wang S; Wang X; Zhu L; Zheng Y; Zou T; Ci H; Dong Q; Qin LX
Signal Transduct Target Ther; 2024 Mar; 9(1):63. PubMed ID: 38453934
[TBL] [Abstract][Full Text] [Related]
3. Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway.
Zhang H; Dong X; Ding X; Liu G; Yang F; Song Q; Sun H; Chen G; Li S; Li Y; Wang M; Guo T; Zhang Z; Li B; Yang L
J Transl Med; 2023 Dec; 21(1):900. PubMed ID: 38082327
[TBL] [Abstract][Full Text] [Related]
4. Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis.
Deng H; Qian X; Zhang Y; Yu W; Yang P
Dig Dis Sci; 2024 Feb; 69(2):476-490. PubMed ID: 38170336
[TBL] [Abstract][Full Text] [Related]
5. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.
Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L
J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939
[TBL] [Abstract][Full Text] [Related]
6. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of β-Catenin.
Zheng Y; Zhou C; Yu XX; Wu C; Jia HL; Gao XM; Yang JM; Wang CQ; Luo Q; Zhu Y; Zhang Y; Wei JW; Sheng YY; Dong QZ; Qin LX
Cell Death Dis; 2018 Feb; 9(2):179. PubMed ID: 29415992
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
[TBL] [Abstract][Full Text] [Related]
9. Liensinine inhibits progression of intrahepatic cholangiocarcinoma by regulating TGF-β1 /P-smad3 signaling through HIF-1a.
Zhu X; Bao W; Xie X; Chen B; Li R; Zhao J; Wu L; Yu Z; Li S; Zhu Q; Chen G; Li J
Mol Carcinog; 2024 Apr; 63(4):772-784. PubMed ID: 38289159
[TBL] [Abstract][Full Text] [Related]
10. Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma.
Zhang GF; Qiu L; Yang SL; Wu JC; Liu TJ
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32140709
[TBL] [Abstract][Full Text] [Related]
11. High expression of protein tyrosine kinase 7 significantly associates with invasiveness and poor prognosis in intrahepatic cholangiocarcinoma.
Jin J; Ryu HS; Lee KB; Jang JJ
PLoS One; 2014; 9(2):e90247. PubMed ID: 24587299
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids.
Lim K; Han C; Xu L; Isse K; Demetris AJ; Wu T
Cancer Res; 2008 Jan; 68(2):553-60. PubMed ID: 18199552
[TBL] [Abstract][Full Text] [Related]
13. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase.
Lin Y; Cai Q; Chen Y; Shi T; Liu W; Mao L; Deng B; Ying Z; Gao Y; Luo H; Yang X; Huang X; Shi Y; He R
Hepatology; 2022 Jan; 75(1):28-42. PubMed ID: 34387870
[TBL] [Abstract][Full Text] [Related]
14. m6A RNA methylation-mediated upregulation of HLF promotes intrahepatic cholangiocarcinoma progression by regulating the FZD4/β-catenin signaling pathway.
Xiang D; Gu M; Liu J; Dong W; Yang Z; Wang K; Fu J; Wang H
Cancer Lett; 2023 Apr; 560():216144. PubMed ID: 36958694
[TBL] [Abstract][Full Text] [Related]
15. Suppression of cholangiocarcinoma cell growth by human umbilical cord mesenchymal stem cells: a possible role of Wnt and Akt signaling.
Liu J; Han G; Liu H; Qin C
PLoS One; 2013; 8(4):e62844. PubMed ID: 23646150
[TBL] [Abstract][Full Text] [Related]
16. Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma.
Wang J; Zhang K; Wang J; Wu X; Liu X; Li B; Zhu Y; Yu Y; Cheng Q; Hu Z; Guo C; Hu S; Mu B; Tsai CH; Li J; Smith L; Yang L; Liu Q; Chu P; Chang V; Zhang B; Wu M; Jiang X; Yen Y
Oncotarget; 2015 Aug; 6(22):18905-20. PubMed ID: 26056085
[TBL] [Abstract][Full Text] [Related]
17. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.
Huang CS; Zhu YQ; Xu QC; Chen S; Huang Y; Zhao G; Ni X; Liu B; Zhao W; Yin XY
Clin Transl Med; 2022 Jun; 12(6):e848. PubMed ID: 35696608
[TBL] [Abstract][Full Text] [Related]
18. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive multiple molecular profile of epithelial mesenchymal transition in intrahepatic cholangiocarcinoma patients.
Huang XY; Zhang C; Cai JB; Shi GM; Ke AW; Dong ZR; Zhang PF; Fan J; Peng BG; Zhou J
PLoS One; 2014; 9(5):e96860. PubMed ID: 24816558
[TBL] [Abstract][Full Text] [Related]
20. Triptolide inhibits intrahepatic cholangiocarcinoma growth by suppressing glycolysis via the AKT/mTOR pathway.
Li L; Wang C; Qiu Z; Deng D; Chen X; Wang Q; Meng Y; Zhang B; Zheng G; Hu J
Phytomedicine; 2023 Jan; 109():154575. PubMed ID: 36610163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
